Results 141 to 150 of about 11,213,687 (295)

Efficacy and Safety of DVDMS-Photodynamic Therapy for Dysphagia in Advanced Esophageal Cancer: A Phase II Clinical Trial. [PDF]

Cancer Sci
Zhou J, Gao S, Yuan J, Chen H, Shu Y, Fan H, Cao Y, Shan T, Dong C, Zhang H, Song Q, Xin B, Zhang H, Lu Z, Shen L.   +14 more
europepmc   +1 more source

Prospecting the protein design landscape

FEBS Letters, EarlyView.
This review outlines the current state of various protein design approaches. We discuss the current possibilities enabled by recently released tools, highlight future avenues to pursue in protein design, and underscore the crucial role of key databases and resources for successful protein design workflows.
Jakob R. Riccabona, Katharina T. Stonig, Jens Meiler, Clara T. Schoeder, Monica L. Fernández‐Quintero   +4 more
wiley   +1 more source

L‐aspartate oxidase provides new insights into fumarate reduction in anaerobic darkness in Synechocystis sp. PCC6803

FEBS Letters, EarlyView.
Synechocystis strains deficient in succinate dehydrogenase (SDH) secrete more succinate than the WT under dark anaerobic conditions, supporting that SDH then primarily acts as SDH, not as a fumarate reductase. L‐aspartate oxidase (Laspo) from Synechocystis is functional under anaerobic conditions, reducing fumarate to succinate.
Kateryna Kukil, Jeffrey A. Hawkes, Cecilia Blikstad, Pia Lindberg   +3 more
wiley   +1 more source

Conditional Estimations for Seamless Phase II/III Clinical Trials Involving Multi-Stage Early Stopping. [PDF]

Stat Med
Zhu S, Yang Y, Yin M, Luo Y, Liang X, Yu S, Duan C.   +6 more
europepmc   +1 more source

Artificial molecular machines and motors—Design and control of nanoscale motion

FEBS Letters, EarlyView.
Molecules are constantly moving because of thermal fluctuations, but random motion alone cannot be exploited to perform directional tasks. Artificial molecular machines use chemical, electrical, or light energy to bias this motion. Molecular shuttles, rotary motors, and supramolecular pumps illustrate how nanoscale movement can be controlled and ...
Leonardo Andreoni, Alberto Credi
wiley   +1 more source

Efficacy and Safety of Co-Ablation Combined With Aintilimab for Metastatic Melanoma to the Liver (CryoCheck-001): A Phase II Trial. [PDF]

MedComm (2020)
Shen L, Lin L, Chen S, Li C, Tang R, Xie L, Wang Y, Li Y, Zou H, Li D, Zhang X, Fan W.   +11 more
europepmc   +1 more source

Leucine‐rich glioma inactivated 1 (LGI1) is a ganglioside‐binding protein

FEBS Letters, EarlyView.
Neuronal hyperexcitability associated with a decrease/absence of the extracellular protein LGI1 has been suggested to be primarily due to the downregulation of Kv1 channel expression. The molecular mechanisms underlying this decrease have not yet been elucidated.
Kévin Debreux, Christian Lévêque, Fodil Azzaz, Marion Sangiardi, Sarosh R Irani, Michael Seagar, Jacques Fantini, Oussama El Far   +7 more
wiley   +1 more source

The effects of heterogeneity on Simon Phase II clinical trial design operating characteristics

, 2010
Christopher N Barnes1, Shesh N Rai21Department of Bioinformatics and Biostatistics, University of Louisville, 2Biostatistics Shared Facility, James Graham Brown Cancer Center, Louisville, KentuckyAbstract: The homogeneity assumption of a Simon Phase II ...
Christopher N Barnes, Shesh N Rai
core  

The ubiquitin system in normal and infected germinal center B cells

FEBS Letters, EarlyView.
The ubiquitin system plays a central role in germinal center (GC) B cells, influencing differentiation to long‐lived memory B cells. Oncogenic gammaherpesviruses gain access to memory B cells by establishing latency in GC B cells. Mapping ubiquitin mechanisms in normal and infected GC B cells will define specific molecular circuits in B cells germane ...
Destiny Davis, Lesly Mejia, Emily K Moser   +2 more
wiley   +1 more source

A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer. [PDF]

Clin Cancer Res
Santin AD, Roque DM, Siegel ER, Ettorre VM, Greenman M, McNamara B, Papatla K, Kailasam A, Buza N, Clark M, Hui P, Dottino P, Ratner E, Bellone S.   +13 more
europepmc   +1 more source